News and Announcements
Kazia Therapeutics shares a video interview with leading cancer researcher Dr Matt Dun
- Published June 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia Therapeutics releases a video interview with leading cancer researcher at the Hunter Medical Research Institute and The University of Newcastle, Dr Matt Dun.
Dr Dun kindly shared some of his time recently to discuss Diffuse Intrinsic Pontine Glioma (DIPG) – the most aggressive form of childhood brain cancer.
DIPG is a deadly disease, with a survival rate of less than 1%, and most commonly affects children between four and 11 years old.
Dr Dun’s research is particularly focused on predicting the progression of DIPG in its early stages and testing new therapies in a bid to improve survival.
Kazia’s brain cancer drug GDC-0084 is one of the therapies he has been working with.
In the video, Dr Dun talks about:
- The incidence of DIPG, with around 15-20 kids diagnosed with the disease each year in Australia and around 300 children in the US
- His very personal motivations to find new treatments for this devastating disease
- His focus on a cancer pathway called PI3 kinase
- How GDC-0084 is one of the most potent PI3 kinase inhibitors and has the potential to cross the blood brain barrier – a very important aspect in treating brain cancer
Watch the video here
Dr Dun’s story was also featured in The Daily Telegraph on the weekend.
About Kazia Therapeutics (ASX:KZA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
